| Literature DB >> 23097634 |
Vinita Chauhan1, Matthew Howland.
Abstract
This study examined alpha (α-) particle radiation effects on global changes in gene expression in human leukemic monocytic cells (THP-1) for the purposes of mining for candidate biomarkers that could be used for the development of a biological assessment tool. THP-1 cells were exposed to α-particle radiation at a dose range of 0 to 1.5 Gy. Twenty-four hours and three days after exposure gene expression was monitored using microarray technology. A total of 16 genes were dose responsive and classified as early onset due to their expression 24 h after exposure. Forty-eight transcripts were dose responsive and classified as late-onset as they were expressed 72 h after exposure. Among these genes, 6 genes were time and dose responsive and validated further using alternate technology. These transcripts were upregulated and associated with biological processes related to immune function, organelle stability and cell signalling/communication. This panel of genes merits further validation to determine if they are strong candidate biomarkers indicative of α-particle exposure.Entities:
Mesh:
Year: 2012 PMID: 23097634 PMCID: PMC3477555 DOI: 10.1100/2012/205038
Source DB: PubMed Journal: ScientificWorldJournal ISSN: 1537-744X
Expression profiles of genes that were shown to be statistically significant 72 h after alpha-particle irradiation at all doses. Statistics based on an n = 5 biological replicates.
| Accession no. | Symbol | FC-D1 | Pv | FC-D2 | Pv | FC-D3 | Pv |
|---|---|---|---|---|---|---|---|
| NM_001040021.1 | CD14 | 3.15 | 0.00 | 5.50 | 0.00 | 5.89 | 0.00 |
| NM_000582.2 | SPP1 | 3.72 | 0.00 | 4.98 | 0.00 | 5.68 | 0.04 |
| NM_021158.3 | TRIB3 | 2.43 | 0.00 | 4.32 | 0.00 | 5.34 | 0.00 |
| NM_000607.1 | ORM1 | 2.49 | 0.00 | 3.62 | 0.00 | 3.67 | 0.00 |
| NM_005980.2 | S100P | 2.28 | 0.00 | 3.25 | 0.00 | 3.44 | 0.00 |
| NM_002965.2 | S100A9 | 2.13 | 0.00 | 2.43 | 0.00 | 2.48 | 0.00 |
| NM_002522.2 | NPTX1 | 1.82 | 0.00 | 2.57 | 0.00 | 2.48 | 0.00 |
| NM_006216.2 | SERPINE2 | 1.75 | 0.00 | 2.51 | 0.00 | 2.44 | 0.00 |
| NM_001122.2 | ADFP | 1.88 | 0.02 | 2.29 | 0.00 | 2.43 | 0.00 |
| NM_005461.3 | MAFB | 1.86 | 0.01 | 2.36 | 0.00 | 2.41 | 0.00 |
| NM_001995.2 | ACSL1 | 1.55 | 0.00 | 2.34 | 0.00 | 2.34 | 0.00 |
| NM_001375.2 | DNASE2 | 1.66 | 0.01 | 2.05 | 0.00 | 2.22 | 0.00 |
| NM_002964.3 | S100A8 | 1.87 | 0.00 | 2.19 | 0.00 | 2.21 | 0.00 |
| NM_000239.1 | LYZ | 2.08 | 0.00 | 2.26 | 0.00 | 2.19 | 0.00 |
| NM_015869.4 | PPARG | 1.68 | 0.00 | 2.13 | 0.00 | 2.17 | 0.00 |
| NM_019058.2 | DDIT4 | 1.57 | 0.00 | 2.15 | 0.00 | 2.15 | 0.00 |
| NM_000104.2 | CYP1B1 | 1.82 | 0.00 | 2.15 | 0.00 | 2.13 | 0.00 |
| NM_003380.2 | VIM | 1.56 | 0.00 | 2.20 | 0.00 | 2.10 | 0.00 |
| NM_000584.2 | IL8 | 2.01 | 0.01 | 2.07 | 0.00 | 2.07 | 0.01 |
| NM_000632.3 | ITGAM | 1.83 | 0.00 | 2.07 | 0.00 | 2.06 | 0.00 |
| NM_006366.2 | CAP2 | 1.51 | 0.00 | 1.92 | 0.00 | 2.03 | 0.00 |
| NM_002928.2 | RGS16 | 1.54 | 0.00 | 1.66 | 0.00 | 1.98 | 0.00 |
| NM_003376.4 | VEGFA | 1.54 | 0.00 | 2.03 | 0.00 | 1.97 | 0.00 |
| NM_003916.3 | AP1S2 | 1.60 | 0.00 | 2.01 | 0.00 | 1.97 | 0.00 |
| NM_004811.1 | LPXN | 1.50 | 0.00 | 2.18 | 0.00 | 1.94 | 0.00 |
| NM_174918.2 | C19orf59 | 1.55 | 0.00 | 2.12 | 0.00 | 1.92 | 0.00 |
| NM_013363.2 | PCOLCE2 | 1.68 | 0.00 | 1.96 | 0.00 | 1.90 | 0.00 |
| NM_000889.1 | ITGB7 | 1.68 | 0.00 | 1.91 | 0.00 | 1.89 | 0.00 |
| NM_001629.2 | ALOX5AP | 1.57 | 0.00 | 1.98 | 0.00 | 1.81 | 0.00 |
| NR_002203.1 | FTHL8 | 1.51 | 0.03 | 1.67 | 0.00 | 1.67 | 0.00 |
| NM_018004.1 | TMEM45A | 1.53 | 0.01 | 1.92 | 0.00 | 1.60 | 0.00 |
| NM_000265.4 | NCF1 | 1.53 | 0.01 | 1.55 | 0.01 | 1.55 | 0.00 |
| NM_003583.2 | DYRK2 | 0.57 | 0.02 | 0.64 | 0.01 | 0.63 | 0.01 |
| NM_152764.1 | C16orf73 | 0.64 | 0.00 | 0.65 | 0.00 | 0.62 | 0.00 |
| NM_001821.3 | CHML | 0.54 | 0.01 | 0.61 | 0.00 | 0.61 | 0.00 |
| NM_002130.6 | HMGCS1 | 0.54 | 0.01 | 0.56 | 0.00 | 0.61 | 0.00 |
| NM_005640.1 | TAF4B | 0.56 | 0.01 | 0.66 | 0.01 | 0.61 | 0.03 |
| NM_001005291.1 | SREBF1 | 0.61 | 0.01 | 0.62 | 0.00 | 0.59 | 0.00 |
| NM_001093772.1 | KIT | 0.58 | 0.00 | 0.60 | 0.00 | 0.57 | 0.00 |
| NM_000527.2 | LDLR | 0.60 | 0.03 | 0.59 | 0.00 | 0.56 | 0.00 |
| NM_000820.1 | GAS6 | 0.62 | 0.02 | 0.64 | 0.00 | 0.54 | 0.00 |
| NM_033445.2 | HIST3H2A | 0.48 | 0.02 | 0.58 | 0.04 | 0.54 | 0.02 |
| NR_002771.1 | DLEU2L | 0.57 | 0.01 | 0.60 | 0.00 | 0.53 | 0.00 |
| XR_001514.1 | DLEU2 | 0.64 | 0.01 | 0.60 | 0.00 | 0.51 | 0.00 |
| NM_005063.4 | SCD | 0.56 | 0.01 | 0.57 | 0.00 | 0.49 | 0.00 |
| NM_001017369.1 | SC4MOL | 0.54 | 0.01 | 0.53 | 0.01 | 0.48 | 0.00 |
| NM_000222.1 | KIT | 0.50 | 0.01 | 0.53 | 0.00 | 0.42 | 0.00 |
| NM_198336.1 | INSIG1 | 0.54 | 0.03 | 0.44 | 0.00 | 0.41 | 0.00 |
Expression profile of genes validated using qRT-PCR. Fold changes and associated P values are indicated for both time points and all doses.
|
Accession no. | Symbol | 0.5 Gy | 1.0 Gy | 1.5 Gy | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| FC-T1 | Pv | FC-T2 | Pv | FC-T1 | Pv | FC-T2 | Pv | FC-T1 | Pv | FC-T2 | Pv | ||
| NM_000582 | SPP1 | 10.865 | 1.2 | 16.3775 | 0.0164 | 15.48 | 4 | 21.56 | 0.0456 | 15.18 | 3 | 22.026 | 0.163 |
| NM_000591 | CD14 | 2.349 | 0.0011 | 7.8024 | 0 | 4.927 | 0.001 | 10.66 | 8 | 6.215 | 2 | 11.534 | 0.01 |
| NM_002522 | NPTX1 | 1.485 | 0.07025 | 3.1824 | 4 | 2.39 | 6 | 3.523 | 2 | 2.599 | 8 | 3.2643 | 0.008 |
| NM_003380 | VIM | 1.2647 | 0.30111 | 2.3705 | 0.0161 | 1.248 | 0.271 | 2.965 | 0.0008 | 1.622 | 0.028 | 3.1475 | 0.004 |
| NM_005461 | MAFB | 1.4789 | 0.15033 | 4.4038 | 0.0001 | 2.139 | 0.012 | 5.656 | 6 | 2.968 | 6 | 4.9452 | 0.017 |
| NM_021158 | TRIB3 | 2.0386 | 0.01668 | 3.2229 | 0.0002 | 5.729 | 3 | 5.373 | 0.0003 | 6.746 | 4 | 5.7073 | 3 |
| NM_005542 | INSIG1 | −1.58 | 0.00271 | −2.01 | 0.0228 | −1.36 | 0.013 | −2.56 | 0.001 | −1.75 | 0.002 | −2.89 | 6 |
| NM_000222 | KIT | −1.18 | 0.20533 | −2.515 | 0.0101 | −1.09 | 0.411 | −3.22 | 0.0014 | −1.49 | 0.014 | −3.35 | 0.001 |
| NM_005980 | S100P | 0.9565 | 0.66173 | 3.9682 | 4 | 1.371 | 0.067 | 4.48 | 2 | 1.632 | 0.002 | 4.5418 | 2 |
| NM_000607 | ORM1 | 1.0251 | 0.83691 | 4.5517 | 0.0003 | 1.406 | 0.048 | 6.452 | 0.0003 | 1.638 | 0.02 | 6.4402 | 5 |
Figure 1Heat map of dose- and time- responsive genes and corresponding fold changes from the microarray data. These genes were statistically significant (P < 0.05) at all doses and time points tested on an n = 5 biological replicates.
Expression profiles of genes that were observed to be dose- and time-responsive using microarray technology.
| Symbol | 0.5 Gy | 1.0 Gy | 1.5 Gy | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| FC-T1 | Pv | FC-T2 | Pv | FC-T1 | Pv | FC-T2 | Pv | FC-T1 | Pv | FC-T2 | Pv | |
| CD14 | 1.77 | 0.00 | 3.15 | 0.00 | 2.63 | 0.00 | 5.50 | 0.00 | 3.08 | 0.00 | 5.89 | 0.00 |
| MAFB | 1.59 | 0.00 | 1.86 | 0.01 | 1.63 | 0.00 | 2.36 | 0.00 | 1.77 | 0.00 | 2.41 | 0.00 |
| NPTX1 | 1.62 | 0.00 | 1.82 | 0.00 | 1.98 | 0.00 | 2.57 | 0.00 | 1.90 | 0.00 | 2.48 | 0.00 |
| SPP1 | 4.61 | 0.00 | 3.72 | 0.00 | 5.05 | 0.00 | 4.98 | 0.00 | 5.17 | 0.00 | 5.68 | 0.04 |
| TRIB3 | 2.40 | 0.00 | 2.43 | 0.00 | 4.46 | 0.00 | 4.32 | 0.00 | 5.39 | 0.00 | 5.34 | 0.00 |
| VIM | 1.56 | 0.00 | 1.56 | 0.00 | 1.62 | 0.00 | 2.20 | 0.00 | 1.62 | 0.00 | 2.10 | 0.00 |
Canonical functions and networks of dose-responsive genes that were differentially expressed 24 h after irradiation
| Category | Score |
|
|---|---|---|
| Networks | ||
| Carbohydrate Metabolism, Lipid | 21 | N/A |
| Diseases and Disorders | ||
| Genetic Disorder | N/A | 4.45 |
| Inflammatory Response | N/A | 3.85 |
| Respiratory Disease | N/A | 4.40 |
| Molecular and Cellular Functions | ||
| Cell-To-Cell Signalling and Interaction | N/A | 4.60 |
| Cellular Development | N/A | 4.80 |
| Cellular Growth and Proliferation | N/A | 3.66 |
| Physiological System Development and Function | ||
| Tissue Development | N/A | 4.25 |
| Haematological System Development | N/A | 4.80 |
| Immune Cell Trafficking | N/A | 4.60 |
| Top Canonical Pathways | ||
| MIF Regulation of Innate Immunity | N/A | 2.05 |
| Toll-like Receptor Signalling | N/A | 2.50 |
Canonical Functions and networks associated with the dose responsive genes that were differentially expressed 72 h after irradiation.
| Category | Score |
|
|---|---|---|
| Networks | ||
| Lipid Metabolism, Molecular | 36 | N/A |
| Carbohydrate Metabolism, | 14 | N/A |
| Developmental Disorder, | 8 | N/A |
| Diseases and Disorders | ||
| Cancer | N/A | 3.39 |
| Haematological Disease | N/A | 3.39 |
| Genetic Disorder | N/A | 3.39 |
| Inflammatory Response | N/A | 3.39 |
| Respiratory Disease | N/A | 2.38 |
| Molecular and Cellular Functions | ||
| Lipid Metabolism | N/A | 3.39 |
| Molecular Transport | N/A | 3.39 |
| Small Molecule Biochemistry | N/A | 3.39 |
| Cell Death | N/A | 3.39 |
| Cellular Movement | N/A | 3.39 |
| Physiological System Development and Function | ||
| Haematological System | N/A | 3.39 |
| Immune Cell Trafficking | N/A | 3.28 |
| Lymphoid Tissue Structure and | N/A | 3.33 |
| Tissue Development | N/A | 3.39 |
| Top Canonical Pathways | ||
| IL-6 Signalling | N/A | 1.09 |
| p53 Signalling | N/A | 1.14 |
| Airway Pathology in Chronic | N/A | 1.35 |
The biological functions associated with the time- and dose-responsive genes as determined using Ingenuity Pathway Analysis software.
| Accession number | Gene | Function |
|---|---|---|
| NM_001040021.1 | CD14 | Immune function, cell immunity differentiation |
| NM_005461.3 | MAFB | Transcription factor, hematopoiesis, |
| NM_002522.2 | NPTX1 | Neural pathways, immune function |
| NM_000582.2 | SPP1 | Immune function, antiapoptosis, |
| NM_021158.3 | TRIB3 | NF-kappa B signalling, AKT 1 signalling, apoptosis |
| NM_003380.2 | VIM | Cell resilience to mechanical stress, organelle stability, |
(a) 24 h
| 0.5 Gy | 1.0 Gy | 1.5 Gy | |
|---|---|---|---|
| Number of Transcripts |
|
|
|
| Common Amongst All Doses (%) |
|
|
|
| Exclusive (%) | 13 (34) | 10 (12) | 87 (53) |
| Upregulated (%) |
|
|
|
| Common Amongst All Doses (%) | 15 (39) | 15 (18) | 15 (51) |
| Exclusive (%) | 13 (34) | 10 (5) | 74 (18) |
| Downregulated (%) |
|
|
|
| Common Amongst All Doses (%) | N/A | 3 (100) | 3 (19) |
| Exclusive (%) | N/A | 0 (0) | 13 (81) |
(b) 72 h
| 0.5 Gy | 1.0 Gy | 1.5 Gy | |
|---|---|---|---|
| Number of Transcripts |
|
|
|
| Common Amongst All Doses (%) |
|
|
|
| Exclusive (%) | 82 (57) | 25 (16) | 57 (30) |
| Upregulated (%) |
|
|
|
| Common Amongst All Doses (%) | 15 (14) | 15 (63) | 15 (8) |
| Exclusive (%) | 82 (75) | 2 (8) | 23 (12) |
| Downregulated (%) |
|
|
|
| Common Amongst All Doses (%) | 32 (97) | 32 (25) | 32 (23) |
| Exclusive (%) | 1 (3) | 23 (18) | 34 (24) |